Financial Assistance

What should I know about insurance coverage for Vectra® DA?


  • Medicare fully covers Vectra DA with no copayment or deductible. Medicare Advantage plans may require a copay.


Private insurance and financial assistance

  • If you have private insurance and cannot afford the copays, deductibles, or other out-of-pocket costs related to the test, you may be eligible for assistance through our CARE program.
  • You may receive an Explanation of Benefits (EOB) – View sample here – from your insurance company, a statement provided regarding the claim we submitted for the test. Crescendo Bioscience may be identified as the test provider on the EOB. Please note: the EOB is not a bill. The balance due that is shown on an EOB may not accurately reflect the actual amount you owe, as it does not indicate financial assistance you may receive or other adjustments to what you owe.
  • If you owe anything, Crescendo Bioscience will bill you directly. The insurance company will not send you a bill for Vectra DA.



  • If you do not have insurance, you may be eligible for financial assistance through our CARE program.


How much will Vectra DA cost me?

The Crescendo Bioscience Commitment

  • At Crescendo Bioscience, we provide reimbursement support and financial assistance to help ensure you have access to Vectra DA through our Crescendo Access & Reimbursement Essentials (CARE) program.

Applying for Financial Assistance Is Easy

  • Contact Crescendo Bioscience or view the CARE application to see if you qualify for financial assistance.
  • Please call 1-877-RHEUMDX (1-877-743-8639) from 6 AM to 5 PM PST, Monday through Friday.
  • You may receive the test at no cost, provided the following requirements are met:
    • Must be a US citizen or legal resident
    • Have been diagnosed with RA
    • Meet household income requirements


Testimonial: Marie Barry, RA Patient Advocate

“I can look back over time and see the progress that I have made. It has really helped me to understand my disease with a long term view.”